Thomas Decker

Thomas Decker is a Scientific Advisor at Valneva. Thomas has over 20 years of experience in the pharmaceutical industry, including management positions at Eurogentec, Pierre Fabre, GSK, and Eli Lilly.

Thomas Decker began their career in 2001 as a Site Closure and Decommissioning Director at Eli Lilly and Company. In 2007, they joined GSK as the Vaccines Business Unit Head for Primary Operations. Thomas held this position for 10 years before moving to Pierre Fabre in 2017 as the Site Head.

In 2020, Thomas Decker joined Eurogentec as the Site Head Biologics. In this role, they were responsible for overseeing the formulation and filling operations for vaccines. Thomas managed a team of 350 employees and had an annual operating budget of €30 million.

Thomas Decker is an expert in the field of vaccines and has extensive experience in managing large teams and budgets. Thomas is a member of several social governance bodies and is actively involved in negotiations with unions.

Thomas Decker's educational career includes a Master of Engineering (MEng) in Electromechanical Engineering from ISIC Mons - Belgium.